Strontium-89 Chloride in Combined Treatment of Hormone Resistant Prostatic Cancer
Hormone resistant phase of prostatic cancer develops after 16-24 months of hormone therapy of metastatic prostatic cancer. Radiopharmaceutical method of treatment is essential for pain control in multiple metastases in the bones; we mean the use of beta-emission isotope strontium-89 chloride (metast...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2020-02-01
|
| Series: | Onkourologiâ |
| Online Access: | https://oncourology.abvpress.ru/oncur/article/view/1244 |